PipelinePharma Logo
PipelinePharma Logo

CTD Dossier Marketplace

Direct connection with CTD dossier (IP) owners and manufacturers

Marketing Authorizations Database

Search across marketing authorization registers
Sign in Get started

Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-202 manufacturers

Filters

Filters

Filters , active

Country of origin : Australia
None products found

pp-202

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
Australia
GMP approvals
TGA
Comments
Indication: Myelofibrosis (MF) — in combination with ruxolitinib in JAK-inhibitor-naïve patients Clinical stage: Phase 2 — ongoing (combination with ruxolitinib) Modality: Small molecule (first-in-class SSAO/VAP-1 inhibitor) Mechanism / Target: First-in-class inhibitor of SSAO (semicarbazide-sensitive amine oxidase) / VAP-1 (vascular adhesion protein-1); reduces inflammatory cell trafficking to the bone marrow, targeting marrow fibrosis and inflammation beyond JAK inhibition alone Route / form: Oral Differentiation: First-in-class SSAO/VAP-1 inhibitor with novel mechanism addressing bone marrow inflammatory trafficking; complementary to JAK inhibition (ruxolitinib); addresses residual disease activity not fully controlled by JAK inhibitors; Parkinson's UK charity collaboration = separate Parkinson's programme only (not co-dev of SNT-5505 for MF);
Manufacturer #39339

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Popular Searches

Amoxicillin manufacturers Atorvastatin manufacturers Benzocaine manufacturers Calcium carbonate manufacturers Cloperastine fendizoate manufacturers Gabapentin manufacturers Hyaluronic acid manufacturers Ibuprofen manufacturers Ivermectin manufacturers Levothyroxine manufacturers Lisinopril manufacturers Losartan manufacturers Magnesium manufacturers Melatonin manufacturers Metformin manufacturers Methotrexate manufacturers Metoprolol manufacturers Omeprazole manufacturers Paracetamol manufacturers Prednisone manufacturers Pregabalin manufacturers Semaglutide manufacturers Testosterone enanthate manufacturers Vitamin B12 manufacturers

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.